New England Journal of Medicine

Date revised: May 23, 2024

The *New England Journal of Medicine* (NEJM) is recognized as one of the world's leading medical journals. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and clinical content to physicians, educators and researchers in nearly every country. In 2019 NEJM was cited more often in scientific literature than any other medical journal and had an impact factor of 74.699. On Dialog, the database includes all full text articles from *The New England Journal of Medicine* excluding meeting notices, "Books Received" and advertising content. The article full text is embargoed for a period of 90 days from publication.

The NEJM's mission is to publish the best research and information at the intersection of biomedical science and clinical practice and to present this information in understandable, clinically useful formats that inform health care delivery and improve patient outcomes. Subjects include but are not limited to:

- Clinical research
- Internal medicine
- Molecular medicine
- Healthcare policy and reform
- Medical ethics
- Medical education

Use New England Journal of Medicine to answer such questions as:

- What is known about the transmission of coronavirus?
- What are the adverse effects of insulin in pregnancy?
- Have any clinical trials been conducted on warfarin?
- Are there systematic reviews on influenza virus vaccines?

Date Coverage
1985-present

Update Frequency
Weekly

Geographic Coverage
International

Document Types
Book reviews, journal articles

Publisher

The New England Journal of Medicine is provided by the NEJM Group of the Massachusetts Medical Society.

Massachusetts Medical Society
860 Winter Street
Waltham, MA 02451-1413
USA

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Sample document

The NEW ENGLAND JOURNAL of MEDICINE

TI

Ribociclib and Endocrine Therapy in Breast Cancer

AU,AUFN,AULN

Rocca, Andrea; Melegari Elisabetta; Palleschi Michela. **The New England Journal of Medicine** 381.16: 1592-1593. Massachusetts Medical Society. (Oct 17, 2019)

PUB

Highlighting: Off | Single | Multi

AB

Abstract (summary) Translate [unavailable for this document]

To the Editor: The MONALEESA-7 (Mammary Oncology Assessment of LEE011's [Ribociclib's] Efficacy and Safety–7) trial (July 25 issue)[1] showed a significant overall survival benefit with the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, ribociclib, to endocrine therapy in patients with luminal advanced breast cancer. In the PALOMA-3 (Palbociclib: Ongoing Trials in the Management of Breast Cancer–3) trial,[2] however, palbociclib added to fulvestrant did not improve overall survival significantly. A higher percentage of patients in the MONALEESA-7 trial (which focused on first-line therapy) had endocrine-sensitive disease[1] or were of Asian race (approximately 30%, vs. 20% in the PALOMA-3 . . .

TX

Full Text Translate [unavailable for this document]

To the Editor: The MONALEESA-7 (Mammary Oncology Assessment of LEE011's [Ribociclib's] Efficacy and Safety–7) trial (July 25 issue)[1] showed a significant overall survival benefit with the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, ribociclib, to endocrine therapy in patients with luminal advanced breast cancer. In the PALOMA-3 (Palbociclib: Ongoing Trials in the Management of Breast Cancer–3) trial,[2] however, palbociclib added to fulvestrant did not improve overall survival significantly. A higher percentage of patients in the MONALEESA-7 trial (which focused on first-line therapy) had endocrine-sensitive disease[1] or were of Asian race (approximately 30%, vs. 20% in the PALOMA-3 trial),[3] both of which are factors that may have contributed to the difference in outcomes. somewhat unexpected in this population of young patients, most of whom (86%) received the study treatment as first-line treatment.[4] In comparison, 80% of the patients in the placebo group in the PALOMA-3 trial received at least one additional line of therapy, although most patients (75%) received the study treatment as a second-line or later line of treatment.[2] We wonder if the extent of subsequent treatments may have affected overall survival, given the documented effect of survival after disease progression on the ability to detect an overall survival benefit.[5]

Dr. Rocca reports having served on advisory boards for Novartis, Pfizer, and Lily. No other potential conflict of interest relevant to this letter was reported.

WC

Word count: **248**

Copyright © 2019 Massachusetts Medical Society. All rights reserved.

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Indexing (details) Cite

SU	Subject	Cyclin-dependent kinase 4; Clinical trials; Breast cancer; Fulvestrant; Cyclin-dependent kinase; Survival; Endocrine therapy; Cancer therapies; Cyclin-dependent kinases
TI	Title	Ribociclib and Endocrine Therapy in Breast Cancer
AU AUFN,AULN	Author	Rocca, Andrea; Melegari Elisabetta; Palleschi Michela [1] [1] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
LA	Language	English
DTYPE	Language of abstract	English
PUB	Document type	Letter To The Editor
VO	Publication title	The New England Journal of Medicine
ISS	Volume	381
PG	Issue	16
	Pagination	1592-1593
PBLOC	Section	Correspondence
DOI	Publisher location	Boston
PD	DOI	http://dx.doi.org/10.1056/NEJMc1911188
	Publication date	Oct 17, 2019
	Document URL	http://dialog.proquest.com/professional/docview/2306304033?accountid=137296
FAV	Copyright	Copyright © 2019 Massachusetts Medical Society. All rights reserved.
UD	First available	2019-10-17
	Updates	2019-10-17 2019-11-15
	Database	New England Journal of Medicine (1985 - current)

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Search fields

Field Name[1]	Field Code	Example	Description and Notes
Abstract	AB	ab("nanoparticle albumin")	Use adjacency and/or Boolean operators to narrow search results.
Abstract present	ABANY	micrornas AND abany(yes)	Add: *AND ABANY(YES)* to a query to limit retrieval to records with abstracts.
All fields	ALL	all(diabetes AND "clinical trial*")	Does not include Full text.
All fields + text	--	diabetes AND "clinical trial*"	Same as ALL field code, plus searches Full text.
Author[1] Author First Name Author Last Name	AU AUFN AULN	au(salas renee) aufn(renee) auln(salas)	Includes all authors. See also First author.
First Author	FAU	fau("dunk, james h")	First name listed in Author field. It is included in Author browse, but its position cannot be specified in the Author browse. See also Author.
Author affiliation	AF	aff(medicine pre/1 "johns hopkins")	
Cited author	CAU	cau("hayes, richard j")	Authors of cited works.
Cited document title	CTI	cti("effect of universal testing and treatment")	Title of cited works
Cited publication date	CYR	cyr(2019)	Year of cited works
Cited publication title	CPUB	cpub("global heart")	Publication title of cited works
Cited reference	RF, REF	rf("effect of universal testing and treatment" and "hayes, richard")	To display cited references click the 'References' hyperlink in the right-hand panel
CODEN	CODEN	coden(nejmag)	All records contain nejmag; use with cross-file searches
Company	CO	co("world health organization")	Infrequently used
DOI	DOI	doi(10.1056/NEJMc1909867)	Digital Object Identifier. Search the portion of the DOI that comes after http://dx.doi.org/.
Document title			See Title
Document type	DTYPE	dtype(book review)	
First available	FAV	fav(20200102) fav(>20200102) fav(20200102-20200119)	Indicates the first time a document was loaded in a specific database on Dialog. It will not change regardless of how many times the record is subsequently reloaded, as long as the accession number does not change.
From database[2]	FDB	"diabetes mellitus" AND fdb(nejm) "diabetes mellitus" AND fdb(1008247)	Useful in multi-file searches to isolate records from a single file. FDB cannot be searched on its own; specify at least one search term then AND it with FDB.
ISSN	ISSN	issn(0028-4793) issn(00284793)	ISSN for all records is 00284793 but does not currently display. Use with cross-file searches.
Issue	ISS	iss(2)	Also searchable via the Look Up Citation tool.

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Location	LOC	loc(baltimore)	
MeSH	MESH, SU	mesh(heart) mesh.exact(heart) mesh("diabetes mellitus, type 2") mesh("heart diseases" LNK (su OR dh))	These are Medical Subject Headings as used in Medline. Explode is not supported, mesh(heart) = 'heart' as a single term and as part of a longer phrase (e.g. 'heart diseases'). mesh.exact(heart) = 'heart' as a single term only. LNK or -- is used to combine a main heading with a subheading. Subheadings can be searched as full terms, abbreviations or quick code.
MeSH term (major)	MJMESH	mjmesh("diabetes mellitus, type 2")	MeSH terms which describe major aspects of the article
Number of pages	PCT	pct(4)	
Pagination	PG	pg(252)	A single number search will sort results for the number as the starting page.
Person	PER	per(osler)	Named person as subject or author of reviewed work.
Publication date	PD	pd(20190829)	
Publication title[2]	PUB	pub("new england journal of medicine")	All records are from the New England Journal of Medicine. Use this search in a multi-file search to narrow results to this journal.
Publication year	YR	yr(2018) yr(2013-2020)	Date range operators are supported. May also be searched using the PY field code.
Publisher location	PBLOC	pbloc(boston)	All records are from the New England Journal of Medicine. Use this search in a multi-file search to narrow results to this journal.
Source type	PT, STYPE	pt(scholarly)	
Subject[1]	SU	su("stem cells") su("colon cancer")	The NEAR operator is not currently supported
Title	TI	ti("randomized trial" NEAR/6 "preterm infants")	Also searchable via the Look Up Citation tool.
Updates	UD	ud(20200116)	The date(s) the record was loaded as a result of an update provided by the supplier
Volume	VO	vo(382)	

1. A lookup/Browse feature is available for this field in the Advanced Search dropdown or in Browse fields.
2. Click the "Field codes" hyperlink at the top right of the Advanced Search page. Click "Search syntax and field codes", then click on "FDB command" to get a list of database names and codes that can be searched with FDB.

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Search tools

Field codes are used to search document fields, as shown in the sample document. Field codes may be used in searches entered on the **Basic Search**, **Advanced Search**, and **Command Line** search pages. **Limit options**, **Look up lists**, and **"Narrow results by" filters** tools are available for searching. Some data can be searched using more than one tool.

Limit options

Limit options are quick and easy ways of searching certain common concepts**.** Short lists of choices are available for:

Source type, Document type

Date limiters are available in which you can select single dates or ranges for date of **publication** and **updated**.

Lookup lists

You can browse the contents of certain fields by using Look Up lists. These are particularly useful to validate spellings or the presence of specific data. Terms found in the course of browsing may be selected and automatically added to the Advanced Search form. Look Up lists are available in the fields drop-down for:

Author, Publication title, Subject

"Narrow Results By" filters

When results of a search are presented, the results display is accompanied by a list of "Narrow results by" options shown on the right-hand panel. Click on any of these options and you will see a ranked list showing the most frequently occurring terms in your results. Click on the term to apply it to ("narrow") your search results. Narrow results by filters in this database include:

Source type, Publication title, Document type, Subject, Classification, Company/Organization, Location, Person, Language, Publication Date

Look up citation

If you need to trace a particular bibliographic reference, use the Look Up Citation feature. Find a link to this toward the top left of the Advanced Search page, or in the drop list under Advanced on any search form; click this and you will go to a page where you can enter any known details of the citation, including: Document title, Author, Publication title, ISSN, Volume, Issue, Page, Publication date, DOI.

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Document formats

Pre-defined document formats are available for viewing and download. Search results can be downloaded with the Download all results, Email, Print and Export/Save options, and when creating an alert. To design your own download format, choose the "Custom" format option and check the fields to be displayed.

Document Format	Fields	Online	Export / Download
Brief view	Title and Publication date.	✓	
Detailed view	Same as Brief view plus a 3-line KWIC window.	✓	
KWIC (Keyword in Context)	Detailed view plus all occurrences of your search terms, highlighted within the fields where the terms occur.	✓	✓
Preview (subscribers only)	Title, Author, Publication title, Pagination, Publication date, Abstract, Subject terms	✓	
Preview (transactional)	Title, Publication Date, abbreviated Abstract, Subject terms.	✓	
Brief citation	Bibliographic record plus partial Indexing minus Abstract	✓	✓
Citation/Abstract	Bibliographic citation plus Abstract and Indexing	✓[3]	✓
Full text	The record with Full text	✓[3]	✓
Full text PDF	PDF version of the original article	✓[3]	
Custom	Choose the fields you want.		✓[4]

[3] In Online-view mode, Dialog gives access to two Document Formats only: *Brief citation*, and the 'most complete' format available. Depending on the database, or the amount of data available for a record, the most complete format may be any one of *Citation*, *Citation/Abstract*, *Full text*, or *Full text – PDF*.
[4] Custom export/download format is available in the following mediums only: HTML, PDF, RefWorks, RTF, Text only, XLS.

Terms & Conditions

Dialog Standard Terms & Conditions apply.

Contact: **Dialog Global Customer Support**
Email: Customer@dialog.com
Within North America **1 800 334 2564**
Outside North America **00 800 33 34 2564**

© 2023 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.